Source comparison
MOTS-c Protocol Comparison
| Protocol Type | Dose per Injection | Frequency | Cycle Length | Target Population | Metabolic Goal | Professional Assessment ||—|—|—|—|—|—|| Preventive (30s) | 5mg | 2x/week | 4 weeks on, 4 weeks off | Ages 30–39 with normal metabolic markers | Preserve insu
This comparison does not assign a generated winner or score.
- | Protocol Type | Dose per Injection | Frequency | Cycle Length | Target Population | Metabolic Goal | Professional Assessment ||—|—|—|—|—|—|| Preventive (30s) | 5mg | 2x/week | 4 weeks on, 4 weeks off | Ages 30–39 with normal metabolic markers | Preserve insulin sensitivity, prevent mitochondrial decline | Best for individuals with baseline metabolic health. Avoids receptor desensitization || Optimization (30s) | 7.5–10mg | 3x/week | 6 weeks on, 4 weeks off | Ages 30–39 with early insulin resistance (HOMA-IR 1.0–2.0) | Restore glucose uptake capacity, reduce visceral fat | Appropriate when fasting insulin >5 μIU/mL or HbA1c >5.2% || Performance (30s) | 10mg | 3x/week, pre-workout | 8 weeks on, 4 weeks off | Ages 30–39 with high training volume | Enhance glucose partitioning, support mitochondrial biogenesis | Pairs well with resistance training. Targets nutrient uptake into muscle tissue || Aggressive (40s+) | 15mg | 3–4x/week | 12 weeks on, 8 weeks off | Ages 40+ with metabolic syndr